非布司他联合氢氯噻嗪治疗慢性肾脏病的临床疗效

Clinical efficacy of febuxostat combined with hydrochlorothiazide on treating chronic kidney disease

目的观察非布司他联合氢氯噻嗪治疗慢性肾脏病的临床疗效。方法选取2019年10月—2020年10月湖南中医药大学第二附属医院收治的慢性肾脏病患者78例,按照随机数字表法分为对照组与观察组,各39例。对照组予以氢氯噻嗪片,观察组在对照组基础上予以非布司他片,疗程均为6个月。比较2组临床疗效,治疗前后肾功能指标[尿微量白蛋白(Alb)、血肌酐(Scr)、尿素氮(BUN)],血清N末端脑钠肽前体、胱抑素C水平,并观察2组不良反应发生情况。结果观察组总有效率为87.17%,高于对照组的66.67%(χ^(2)=4.622,P=0.032)。治疗6个月后,2组Alb、Scr、BUN低于治疗前,且观察组低于对照组(P<0.01)。治疗6个月后,观察组血清N末端脑钠肽前体、胱抑素C水平低于治疗前,且观察组低于对照组(P<0.01)。观察组不良反应总发生率为7.69%,与对照组的10.26%比较,差异无统计学意义(χ^(2)=0.157,P=0.692)。结论非布司他联合氢氯噻嗪治疗慢性肾脏病患者的临床疗效确切,可有效改善肾功能及血清N末端脑钠肽前体、胱抑素C水平,且安全性较高。

Objective To observe the clinical efficacy of febuxostat combined with hydrochlorothiazide on treating chronic kidney disease.Methods A total of 78 cases of patients with chronic kidney disease were selected from October 2019 to October 2020 in the Second Affiliated Hospital of Hunan University of Traditional Chinese Medicine,which were divided into control group and observation group according to the random number table method,with 39 cases in each group.The control group was given hydrochlorothiazide tablets,while the observation group was given febuxostat tablets on the basis of the control group.Clinical efficacy,renal function indexes(Alb,Scr,BUN),serum N-terminal pro-brain natriuretic peptide and cystatin C levels before and after treatment were compared between the two groups,and the incidence of adverse reactions were observed.Results The total effective rate of the observation group was 87.17%,higher than 66.67%of the control group(χ^(2)=4.622,P=0.032).After treatment,Alb,Scr and BUN in the two groups were lower than those before treatment,and those in the observation group were lower than those in the control group(P<0.01).After treatment,the levels of serum N-terminal pro brain natriuretic peptide and cystatin C in the observation group were lower than those before treatment,and those in the observation group were lower than those in the control group(P<0.01).The total incidence of adverse reactions in the observation group was 7.69%,compared with 10.26%in the control group,the difference was not statistically significant(χ^(2)=0.157,P=0.692).Conclusion Febuxostat combined with hydrochlorothiazide have an exact clinical effect on treating chronic kidney disease,which can effectively improve renal function and serum N-terminal pro brain natriuretic peptide and cystatin C levels,and with high safety.